Barclays Maintains Overweight on Boston Scientific, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Negative 88.3%

Neg 88.3% Neu 0% Pos 0%

Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:BSX) with a Overweight and lowers the price target from $124 to $100.